Atrial fibrillation is a common heart condition where the heart beats irregularly, increasing the risk of stroke and other serious health issues. According to the SINGLE-AF trial, which was presented at the ESC Congress 2026 and published in the New England Journal of Medicine, patients with an intermediate risk of stroke who were treated with direct oral anticoagulants (DOACs) had a 69% lower risk of serious clinical events compared to those who received no anticoagulation. The study was conducted across 18 medical centers in South Korea and involved 1,803 participants with atrial fibrillation who had a CHA2DS2-VASc score of 1 in men or 2 in women. This score is used to assess stroke risk in patients with atrial fibrillation. Participants were randomly assigned to receive either apixaban 5 mg twice daily, rivaroxaban 20 mg once daily, or no anticoagulation. After 24 months of follow-up, the trial found that the primary endpoint—comprising stroke, systemic embolism, major bleeding, and cardiovascular death—was significantly reduced among those taking DOACs. Only 0.5% of patients on DOACs experienced serious events, compared to 1.5% of those not receiving anticoagulation. The reduction was mainly due to fewer ischemic strokes, with 0.1% of DOAC-treated patients experiencing such strokes, compared to 1.1% of those not on anticoagulation. The study also found no significant increase in major bleeding among those taking DOACs. Only 0.3% of DOAC-treated patients had major bleeding, compared to 0.5% of those who did not receive anticoagulation. These findings suggest that DOACs may be a safer and more effective treatment option for patients with intermediate stroke risk due to atrial fibrillation. The results of the SINGLE-AF trial may influence future treatment guidelines and reimbursement policies for atrial fibrillation. As more data becomes available, healthcare providers and policymakers may consider updating recommendations to reflect the benefits of DOACs in this patient group.